



ABN 53 075 582 740

ASX ANNOUNCEMENT

21 July 2017

Bionomics Presents at 13th Annual Bioshares Biotech Summit

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, is presenting on BNC210 as a treatment for Post-Traumatic Stress Disorder (PTSD) at the 13th Annual Bioshares Biotech Summit in Queenstown New Zealand.

The presentation by CEO & Managing Director Deborah Rathjen is at the Neurotech session tomorrow. The Bioshares event is on 21-22 July with delegates from the biotech industry as well as biotech analysts and investors.

The Neurotech session at this year's summit is partly about the lack of effective treatment options for CNS disorders such as Alzheimer's and anxiety. There are more people who suffer from these diseases due to ageing populations and more demanding and hectic lifestyles.

There are many gaps in effective treatments of these diseases and this session gives Bionomics an opportunity to outline the strong commercial opportunities that exist for BNC210 including in the PTSD market. Recent external analysis has indicated that the addressable US market potential of BNC210 in PTSD is US\$4.7 billion.

A copy of the slide deck is now available on Bionomics' website, www.bionomics.com.au.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern Investor Relations
Beth DelGiacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210,

currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada).

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.